Literature DB >> 15766724

Semiautomated cell-free conversion of prion protein: applications for high-throughput screening of potential antiprion drugs.

Leonid Breydo1, Olga V Bocharova, Ilia V Baskakov.   

Abstract

Transmissible spongiform encephalitis (TSE) is a lethal illness with no known treatment. Conversion of the cellular prion protein (PrP(C)) into the infectious isoform (PrP(Sc)) is believed to be the central event in the development of this disease. Recombinant PrP (rPrP) protein folded into the amyloid conformation was shown to cause the transmissible form of prion disease in transgenic mice and can be used as a surrogate model for PrP(Sc). Here, we introduced a semiautomated assay of in vitro conversion of rPrP protein to the amyloid conformation. We have examined the effect of known inhibitors of prion propagation on this conversion and found good correlation between their activity in this assay and that in other in vitro assays. We thus propose that the conversion of rPrP to the amyloid isoform can serve as a high-throughput screen for possible inhibitors of PrP(Sc) formation and potential anti-TSE drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15766724     DOI: 10.1016/j.ab.2005.01.003

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  9 in total

Review 1.  Emergence and natural selection of drug-resistant prions.

Authors:  James Shorter
Journal:  Mol Biosyst       Date:  2010-04-27

2.  Nonpolar substitution at the C-terminus of the prion protein, a mimic of the glycosylphosphatidylinositol anchor, partially impairs amyloid fibril formation.

Authors:  Leonid Breydo; Ying Sun; Natallia Makarava; Cheng-I Lee; Vera Novitskaia; Olga Bocharova; Joseph P Y Kao; Ilia V Baskakov
Journal:  Biochemistry       Date:  2007-01-23       Impact factor: 3.162

3.  Proteolysis of prion protein by cathepsin S generates a soluble beta-structured intermediate oligomeric form, with potential implications for neurotoxic mechanisms.

Authors:  Oxana Polyakova; Denise Dear; Igor Stern; Stephen Martin; Elizabeth Hirst; Suleman Bawumia; Angus Nash; Guy Dodson; Igor Bronstein; Peter M Bayley
Journal:  Eur Biophys J       Date:  2008-09-24       Impact factor: 1.733

Review 4.  Complex polyamines: unique prion disaggregating compounds.

Authors:  Surachai Supattapone; Justin R Piro; Judy R Rees
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-11       Impact factor: 4.388

Review 5.  Recent advances in prion chemotherapeutics.

Authors:  Valerie L Sim; Byron Caughey
Journal:  Infect Disord Drug Targets       Date:  2009-02

6.  A simple in vitro assay for assessing the efficacy, mechanisms and kinetics of anti-prion fibril compounds.

Authors:  Carol L Ladner-Keay; Li Ross; Rolando Perez-Pineiro; Lun Zhang; Trent C Bjorndahl; Neil Cashman; David S Wishart
Journal:  Prion       Date:  2018-10-09       Impact factor: 3.931

Review 7.  Prion propagation in vitro: are we there yet?

Authors:  Chongsuk Ryou; Charles E Mays
Journal:  Int J Med Sci       Date:  2008-11-11       Impact factor: 3.738

8.  Shaking alone induces de novo conversion of recombinant prion proteins to β-sheet rich oligomers and fibrils.

Authors:  Carol L Ladner-Keay; Bethany J Griffith; David S Wishart
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

Review 9.  Recombinant PrP and Its Contribution to Research on Transmissible Spongiform Encephalopathies.

Authors:  Jorge M Charco; Hasier Eraña; Vanessa Venegas; Sandra García-Martínez; Rafael López-Moreno; Ezequiel González-Miranda; Miguel Ángel Pérez-Castro; Joaquín Castilla
Journal:  Pathogens       Date:  2017-12-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.